Renal Anemia | Disease Landscape & Forecast | G7 | 2022

Renal anemia is a common complication of chronic kidney disease (CKD). Although there are treatments for the disease, physicians, patients, and healthcare systems have concerns about their limitations. Delivery, safety issues, and tightening healthcare budgets have resulted in increased scrutiny of the effectiveness and tolerability of such therapies as intravenous (IV) iron and erythropoiesis-stimulating agents (ESAs). The renal anemia therapy market will expand over the 2021-2031 study period, fueled by increasing prevalence and demand for new drugs that can effectively, safely, and conveniently control the disease. The launches of several hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors are expected during the study period. Although these new therapies offer advantages over current therapies, they will face major challenges, including reimbursement hurdles and an increasingly stringent regulatory environment.


  • What are the opportunities for marketers of the emerging oral HIF-PH inhibitors to promote their noninvasive route of administration, particularly for patients not on dialysis?
  • Will establishing cardiovascular (CV) safety be key for the market uptake of HIF-PH inhibitors, in view of the CV issues associated with current therapies?
  • With the imminent availability of biosimilars in the United States, how will emerging therapies that offer only incremental improvements over existing therapies fare?


  • Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
  • Primary research: 20 country-specific interviews with thought-leading nephrologists. Supported by survey data collected for this and other Clarivate research.
  • Epidemiology: Prevalence of renal anemia by country and diagnosed / drug-treated rates.
  • Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
  • Market forecast features: 10-year, annualized, drug-level sales and patient share of key renal anemia therapies through 2031, segmented by brands / generics.


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Login to access report